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ABSTRACT
Introduction: Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third most common cancer-
related cause of death in the world. According to the stage of the disease, each patient is allocated to a different treatment 
option. Liver transplantation, along with surgical resection, is the only totally therapeutic option and is primarily indicated 
in HCC patients with underlying cirrhosis. However, the restricted number of liver grafts imposes difficulties in selecting 
the most suitable patients to receive those limited grafts and therefore certain criteria have been proposed. The Milan 
criteria are currently the most widely accepted and utilized criteria around the world, despite their restrictiveness. In an 
attempt to assist HCC patients exceeding them, but with a potential to display acceptable survival outcomes, undergo liver 
transplantation, research teams worldwide suggest expanded criteria based on their findings. Some of the most broadly 
known are the University of California, San Francisco (UCSF), Kyoto, Tokyo, Hangzhou and up-to-7 criteria. On the other 
hand, in order to expand the liver donor pool, grafts may be accepted from living, non-heart beating, elderly, steatotic, or 
even HCV-infected donors, in addition to the use of split livers with both advantages and disadvantages. The aim of this 
review is to thoroughly present the current situation of liver transplantation for HCC patients, with a focus on the criteria 
used and emerging challenges presented. Core tip:  Hepatocellular carcinoma (HCC) is the third most common malignancy 
worldwide and liver transplantation represents the treatment of choice, particularly in the setting of cirrhosis. Lack of 
grafts led to the utilization of certain criteria in order to determine the eligibility of an HCC patient to access the waiting 
list. The most widely accepted are the Milan criteria, even though they are thought off as too restrictive. Consequently, 
transplant research groups all over the world published their own criteria, which showed acceptable outcomes. Living 
donor liver transplantation and other extended-criteria grafts have been proposed as an alternative to reduced donations. 
Ziogas IA, Tsoulfas G. The evolution of criteria for liver transplantation for hepatocellular carcinoma: from Milan to San 
Francisco and all around the world!
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common 
primary neoplasm of the liver (85-90%)1 and, in spite 
of the several advances in oncology and surgery we 
witnessed in the 21th century, it still represents the 
fifth most frequent carcinoma and the third most 
common malignancy-related cause of mortality 
worldwide2.  It is well known that liver cirrhosis is 
a major feature usually accompanying HCC (70-
90%)2, mostly after HBV or HCV infection or even 
alcoholic liver disease depending on the geographical 
parameters. Specifically, the incidence of HCC tends 
to be higher in Asia (>20/100000) in comparison 
with North America and Europe (<5/100000)3, but 
interestingly the development and the establishment 
of the vaccine against HBV in Asian countries resulted 
in a prominent decrease in HCC’s occurrence during 
the last decades4. On the contrary, it shows an increase 
over the past years in low-rate countries such as USA, 
UK and Australia1,5 mainly attributed to an increase in 
HCV incidence and to an improvement in survival of 
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cirrhotic patients, thus indicating the significance of 
further improving the treatment modalities that can 
be implemented in order to manage this highly fatal 
type of cancer.
Regarding the available treatment options, there is a 
wide variety to choose from always depending on the 
individual parameters of the HCC patient, such as the 
tumor’s characteristics (size and number of neoplastic 
nodules and invasion of vascular compartments), the 
liver’s functional capacity (Child-Pugh score) and the 
physiologic reserve (i.e. Eastern Cooperative Group 
performance status)6–8. The staging system that seems to 
take all of these aspects into consideration, which is also 
suggested by the European Association for the Study of the 
Liver-European Organization for Research and Treatment 
of Cancer (EASL-EORTC) guidelines, is the Barcelona 
Clinic Liver Cancer (BCLC) classification(Figure1)9. 
Nevertheless, the only therapeutic approaches that 
have shown total cancer remission and cancer-free 
survival are the surgical resection and orthotopic liver 
transplantation (OLT), hence indicating that surgery is 
the cornerstone of HCC treatment.
OLT has the theoretical advantage of simultaneously 
treating HCC and cirrhosis at the same time, and as such 
it would be the ideal treatment in a fictitious world of 
graft abundance. Unfortunately, it is evident that there 
is a great absence of donor organs worldwide and 
consequently potential transplant candidates should 
firstly undergo an objective prioritization process 
in order to determine the ones with the greatest 
potential to benefit from OLT and thus allocate liver 
grafts accordingly. Although Dr. Thomas Starzl carried 
out the first human liver transplantation in 1963, it was 
not until the 1990s that Mazzaferro et al published the 
famous Milan criteria for liver transplantation10. These 
were the findings, that in combination with Bismuth’s 
studies11,12, achieved the establishment of OLT as the 
appropriate therapy for patients with small HCC and 
cirrhosis. Therefore, they facilitated the transition of 
liver transplantation from the experimental level to 
the current life-saving procedure for a continuously 
increasing number of liver failure patients.
New challenges have emerged, though, over the past 
years in regard to liver transplantation, especially 
associated with the attempt of increasing the liver 
donor pool, as deceased donor liver transplantation 
(DDLT)-the standard option-does not seem to fulfill the 
need for liver grafts. Living donor liver transplantation 
(LDLT) has gained a great deal of attention, especially 
in eastern countries, and its results seem promising. 
Split liver transplantation (SLT) is also an alternative 
option by which more recipients can benefit from a 
single donor organ and its effects, especially in the 
pediatric population in need, have been tremendous. 
Moreover, many HCC patients with advanced stage 
tumor receive pre-transplant treatments in order to 
meet certain criteria for OLT (downstaging strategy) or 
receive bridging therapy, while on the waiting list, so 
as to have the course of their disease remain constant. 
Last but not least, new anti-HCV therapies have a 
significant effect in liver transplant candidates and 
recipients with HCV-related liver disease.
On the whole, the constant need for prioritization 
and the accompanying advances in liver surgery and 
research need to be followed by the establishment and 
the subsequent transformation of liver transplantation 
criteria. Thus, the aim of this review is to thoroughly 
describe the evolution of those criteria (Table 1) and 
OLT in general.
DIFFERENT CRITERIA AND EVOLUTION
MILAN CRITERIA
The Milan criteria proposed by Mazzaferro et al in 
199610 are the most broadly accepted ones worldwide. 
Specifically, the achievement of 85% and 92% 4-year 
overall and recurrence-free survival, respectively, led 
to their adoption by the United Network for Organ 
Sharing (UNOS) as the criteria of choice for objectively 
choosing the suitable early-HCC patients for liver 
transplantation. According to the Milan criteria 
patients receiving liver transplantation should have 
a single tumor ≤ 5 cm in diameter or no more than 
three nodules ≤ 3 cm in diameter and no evidence 
of vascular or extrahepatic invasion.  Although these 
findings correlated with great survival and oncologic 
outcomes, they seem to be quite restrictive and 
only a small portion of the HCC patients that could 
benefit from liver transplantation does fulfill them. 
Additionally, the whole biological course of such a 
unique and heterogeneous type of cancer cannot be 
simply assessed only by size and number. Thus, a great 
deal of experts in liver transplantation proposed their 
own expanded criteria, many of which incorporate the 
evaluation of certain biological markers. Nevertheless, 
this consecutive tendency for expanding them cannot 
always be followed by an adequate evidential value, 
as most studies are retrospective cohorts and there is 
a profound absence of outside validation13. In general, 
the “metro ticket paradigm” perfectly describes the 
current situation: the longer distance we cover away 

















from the conventional criteria, the higher the price we 
will have to pay in terms of increased recurrence14.
UNIVERSITY OF CALIFORNIA SAN FRANCISCO 
(UCSF) CRITERIA
In an effort to expand the Milan criteria, a retrospective 
study by Yao et al15 reported that patients with larger 
lesions could also exhibit improved survival with OLT. 
To elaborate this, they proposed the University of 
California San Francisco (UCSF) criteria, according to 
which patients could undergo OLT if they presented 
with a single lesion ≤ 6.5 cm in diameter or ≤ 3 lesions 
with the largest one ≤ 4.5 cm in diameter and an 
overall tumor diameter ≤ 8 cm. Significantly, the 1- and 
5-year survival rates were 90% and 75.2%, respectively. 
In addition, the group of HCC patients exceeding the 
Milan, but fulfilling the UCSF criteria showed 86% 
2-year survival percentage. Even though their data 
were based on histopathological examination of the 
explanted hepatic lesion, Yao et al16 also validated 
the USCF criteria in accordance to pre-OLT imaging 
reporting a 5-year recurrence-free survival of 80.7%. 
Notably, the rate of expansion beyond the Milan 
criteria was 16.3%17.
PITTSBURGH CRITERIA
In an attempt to improve the predictive values of 
cancer-free survival in HCC patients receiving OLT, 
Marsh et al18 evaluated the association between the 
pathologic tumor-node-metastasis (pTNM) staging 
system and cancer-free survival, which led to the 
recognition of the no contact point. Instead they 
came up with a modification of the pTNM criteria, 
the so-called Pittsburgh criteria, according to which 
the prognosis can be determined by assessing the 
depth of vascular invasion, lymph node status, lobar 
distribution, as well as size of the largest lesion, 
although the number of nodules did not seem to play 
a key role. Unfortunately, the major limitation of this 
system is that metastasis to lymph nodes or invasion 
of vessels cannot be easily determined preoperatively, 
hence it did not gain wide acceptance.
UNIVERSITY CLINIC OF NAVARRA CRITERIA
In 2001, Herrero et al19 reported that patients with 
HCC and cirrhosis could benefit from OLT, as long as 
they presented with a solitary tumor ≤ 6 cm or up 
to three nodules ≤ 5 cm in diameter. These are the 
University Clinic of Navarra (CUN) criteria and the 
aforementioned study showed that the estimated 
1-, 3- and 5-year survival rates were 87%, 79% and 
79%, respectively, while the 1-, 2- and 3-year actuarial 
recurrence-free survival ones were 87%, 82% and 
70%, respectively. Interestingly, bilobar disease, viral 
etiology of cirrhosis, invasion of vessels and TNM 
stage IV were significant characteristics of patients 
displaying a decreased recurrence-free survival. An 
important recommendation from Herrero et al is that 
HCC patients with radiological TNM stage IV should 
not be considered for OLT. The CUN criteria also 
exhibited an expansion estimate of 19.6% beyond the 
Milan criteria17.
MOUNT-SINAI CRITERIA
Roayaie et al20 attempted another criteria expansion 
at Mount-Sinai, New York arguing that the number 
of lesions should not be taken into consideration. In 
other words, the proposed criteria included patients 
with any number of nodules, as long as the diameter 
of each one was 5-7 cm. They demonstrated a 5-year 
recurrence rate of 55%, which unfortunately falls short 
of that of the Milan criteria.
EDMONTON CRITERIA
On a similar pattern, Kneteman et al21 suggested an 
extended version of OLT criteria consisting of a solitary 
nodule < 7,5 cm, or any number of lesions with a size 
< 5 cm for each one. The demonstrated 4-year survival 
was 82.9% in comparison with the 87.4% of the Milan 
criteria arm of the study.
DALLAS CRITERIA
Onaca et al22 analyzed data from 1206 HCC patients 
from the International Registry of Hepatic Tumors in 
Liver Transplantation and suggested that more patients 
could benefit from OLT if the criteria expanded to one 
nodule ≤6 cm in diameter, or two to four lesions each 
one ≤ 5 cm in diameter. Survival rates were similar to 
that of the Milan criteria, as 5-year recurrence-free 
survival was 63.9% for a single tumor 5.1-6.0 cm in 
diameter and 64.6% for 2-4 lesions, with the largest 
being 3.1-5.0 cm, versus the 61.8% observed in those 
fulfilling the Milan criteria.
TOKYO CRITERIA
During the last decade, Asian centers showed an 
increased interest in expanding the Milan criteria. It 
was the University of Tokyo23, specifically, that laid the 
foundation for LDLT by introducing historically the 
first criteria for this operation. The so-called 5-5 rule 
indicated that HCC patients are eligible for LDLT if they 
have ≤ 5 tumors not exceeding a diameter of 5cm. This 
study reported a 5-year overall and recurrence-free 
survival of 75% and 90%, respectively. Another study 
incorporating 139 HCC patients receiving LDLT from 
1996 until 2015 showed that overall and recurrence-

















free survival were similar between patients meeting Milan 
and Tokyo criteria24. Shindoh et al proposed another 
subset of criteria based on the Tokyo ones25. In other 
words, the additional prerequisites they added to the 
Tokyo criteria were a serum a-fetoprotein (AFP) level ≤ 250 
ng/mL and a serum Des-Gamma-carboxy prothrombin 
(DCP) level, a serum marker of primary HCC26,≤ 450 mAU/
mL. The observed 5-year overall and recurrence-free 
survival were 84% and 96.8%, respectively.
KYOTO CRITERIA
Another group, also from Japan, proposed the Kyoto 
criteria27, which suggest that LDLT can be effectively 
performed in HCC patients with ≤ 10 nodules all of 
which are ≤ 5 cm in diameter and with a serum DCP 
≤ 400 mAU/mL. The 125 patients included displayed 
a 5-year overall survival rate of 86.7%, while patients 
exceeding the Milan but meeting the Kyoto criteria 
showed a 7.3% 5-year recurrence rate in comparison 
with the 9.7% of the patients meeting the Milan 
criteria. These criteria were also recently prospectively 
evaluated exhibiting a 5-year overall survival rate and 
recurrence rate of 82% and 7%, respectively, thus 
highlighting that by this expansion more patients 
could benefit from LDLT with acceptable outcomes28.
KYUSHU UNIVERSITY INDICATIONS
Additionally, another Japanese team of researchers, 
this time from Kyushu University, in an effort to 
evaluate the extent that liver transplantation criteria 
could be expanded, treated 60 HCC patients with 
LDLT [29]. The inclusion criteria were the absence of 
both extrahepatic metastases and vascular invasion, 
without preclusion of patients in regard to number 
or size of HCC lesions; for the record more than half 
of them exceeded the Milan criteria (67%). Their 
conclusions were that patients with DCP > 300 mAU/
mL and > 5 cm in diameter will have a significantly 
worse prognosis and increased recurrence percentage.
HANGZHOU CRITERIA
A Chinese research team established a new subset of 
HCC patient selection for OLT criteria, the Hangzhou 
criteria30. These consist of a) an overall tumor diameter 
≤ 8 cm, or b)> 8 cm with a histopathological grade I 
or II and pre-transplantation AFP ≤ 400 ng/mL. The 
reported 1-, 3-, 5-year overall survival and cancer-free 
recurrence estimates were 92.8%, 70.7%, 70.7%, and 
83.7%, 65.6%, 62.4%, respectively. Interestingly, there 
was no statistically significant difference between 
the patients meeting the Hangzhou and the Milan 
criteria as to survival rates. A recent study evaluating 
the percentage of expansion beyond the Milan criteria 
reported that patients fulfilling those criteria exhibited 
the highest expansion rate (51.5%) among those 
tested, while type a presented with markedly increased 
survival rates compared to type b17. In 2015, Xiao et 
al31 proposed a combination of the Hangzhou criteria 
with the measurement of Neutrophil-lymphocyte 
ratio (NLR). It is widely known that elevation of this 
marker correlates with worse prognosis of HCC, and 
as a result they demonstrated that patients with NLR 
≤4 and within the Hangzhou criteria exhibit the best 
prognosis and recommend these criteria as the gold-
standard for the mainland of China.
ASAN CRITERIA
The Asian tradition of expanding the Milan criteria, 
especially in HCC patients undergoing LDLT, was 
carried on by the Asan Medical Center in South Korea. 
In particular, the Asan criteria, which are based on 
explant pathology just as the UCSF criteria, include≤ 
5cm in diameter, ≤ 6 nodules and no gross invasion 
of the vessels[32]. The 1-, 3- and 5-year overall survival 
rates according to the Asan criteria were 88.1%, 81.9% 
and 76.3%, respectively. When compared to Milan and 
UCSF, Asan criteria displayed similar survival rates. An 
advantage of these criteria is that their application by 
preoperative assessment was markedly associated 
with the survival and recurrence rates as to the 
histopathological evaluation of the explanted specimen. 
This shows that patient selection could be also partially 
based on pre-transplant radiographic findings, despite 
the potential deviations that may arise33.
VALENCIA CRITERIA
It was in 2008 that “the baton was handed over” to 
Silva et al [34] to expand the OLT criteria. Specifically, 
they proposed the Valencia criteria, which include up 
to three lesions, each no larger than 5 cm in diameter 
and a total diameter ≤ 10 cm, based on radiology. 
The 1-, 3- and 5-year survival rates were 85%, 72% 
and 67%, respectively, while the 1-, 3- and 5-year 
recurrence rates were 5%, 9% and 11%, respectively. 
After histopathological examination of the explanted 
tumors, those exceeding the Milan criteria, being 
bilobar and with poor differentiation showed the 
highest underestimation rates compared to the 
radiological estimates. The retrospective character, 
though, of this study highlights the need for larger 
prospective studies.


















The Shanghai criteria proposed by Fan et al35 consist 
of a single lesion ≤ 9 cm in diameter, or no more than 
three nodules with the largest ≤ 5 cm in diameter, 
overall tumor diameter ≤ 9 cm without extrahepatic 
metastasis, lymph node or macrovascular invasion. 
This study included 1,078 HCC patients with 1- and 
5-year overall survival rates of 85.8% and 78.1%, 
respectively, while the cancer-free survival rates were 
59.9% and 52.6%, respectively. It was the largest group 
of patients with HCC being assessed for OLT criteria in 
China and notably 45% more patients can benefit by 
the adoption of these findings with adequate survival 
outcomes. A major limitation, however, is that most 
of the patients were HBV-positive and as a result the 
Shanghai criteria could possibly be generalized only 
for HCCs of HBV infection origin.
UP-TO-7 CRITERIA
Even Mazzaferro showed an interest in expanding the 
Milan criteria, therefore publishing with his colleagues 
the up-to-7 criteria, according to which the sum of 
tumor number and the size of the largest nodule must 
be ≤ 7 cm in diameter, without any microvascular 
invasion[14].The 5-year overall survival of 283 patients 
without microscopic invasion of the vessels meeting 
these criteria was 71.2%. This study provides robust 
data on adequately and accurately estimating the 
results of OLT in HCC patients. Nevertheless, the 
absence of cancer grading, reason of death, etiology 
behind the origin of cirrhosis and HCC, response rates 
to preoperative therapeutic modalities and molecular 
marker testing does not seem to classify these criteria 
as an excellent patient selection system.
TTV/AFP CRITERIA BY TOSO ET AL
After extracting data from the Scientific Registry of 
Transplant Recipients (SRTR), Toso et al36 suggested 
that patient survival is clearly associated with the total 
tumor volume (TTV) and the pre-transplant serum 
AFP levels. After validating their suggestion not only 
retrospectively36, but recently also prospectively37 they 
proposed their criteria including total tumor volume 
≤ 115 cm3 and preoperative serum AFP ≤ 400 ng/mL, 
which demonstrated a 4-year overall survival rate of 
74.6% in their 2015 study. Their contribution was major 
due to the fact that these expanded criteria could be 
safely implemented in transplant centers with at least 
8-month waiting time.
AFP-TTD CRITERIA BY LAI ET AL
In 2012, Lai et al38 proposed the combination of both 
biological and morphological characteristics to be 
taken into consideration for HCC patient selection for 
OLT. To elaborate this, they stated that patients with 
serum AFP ≤ 400 ng/mL and total tumor diameter 
(TTD) ≤ 8 cm exhibit adequate survival estimates with 
a 5-year disease-free survival rate of 74.4%. However, 
this study has the limitations of a retrospective study 
and its wider application is questionable because of 
possible selection bias.
WARSAW CRITERIA
One of the recent proposals for expanding the OLT 
criteria came from Poland by Grat et al39. These are the 
Warsaw criteria and include HCC patients exceeding 
the Milan, but meeting the UCSF, or the up-to-7 
criteria plus an AFP serum level below 100 ng/mL. 
The observed 5-year overall survival and recurrence-
free survival rates were both 100%, which is a unique 
finding. Another study from Grat et al40 showed similar 
survival benefits, hence indicating that AFP is a useful 
marker for patient selection. 
NLR-CRP CRITERIA BY NA ET AL
In 2014, Na et al41 in order to enlarge the LDLT pool 
evaluated 224 patients by measuring inflammatory 
markers, such as NLR and C-reactive protein (CRP). 
Specifically, HCC patients with NLR equal or greater 
to 6.0 or CRP equal or greater to 1.0 demonstrated 
significantly lower cancer-free and overall survival rates 
when compared to patients with NLR < 6.0 or CRP < 1.0.
NCCK CRITERIA
The efficacy of fluorine-18-fluorodeoxyglucose (18-
FDG) positron emission tomography/computed 
tomography (PET/CT) in detecting extrahepatic 
metastases and recurrence in HCC patients has been 
broadly confirmed42,43. In 2015, Lee et al44 published 
a study including 280 patients who received LDLT at 
the National Cancer Center and reported that HCC 
patients exceeding the Milan criteria with a negative 
PET/CT and overall tumor size <10 cm demonstrated 
overall survival and recurrence-free survival rates 
similar to those meeting the Milan criteria. In 2016, 
they proposed the so-called National Cancer Center 
Korea (NCCK) criteria, according to which patients 
selected for LDLT should present with negative PET/
CT assessment and a total tumor size < 10 cm45.
EXTENDED TORONTO CRITERIA
After reporting the results of a first retrospective 
cohort study[46], a research group went on with a 
second validation prospective cohort study47 in an 
effort to prove that tumor size and number are not 
the only aspects that should be considered in patient 
selection for OLT, but tumor differentiation and tumor-

















related symptoms should be taken into consideration 
as well. These are named the extended Toronto criteria 
(after the validation study) and consist of no vascular 
invasion, no extrahepatic metastasis, no cancer-related 
symptoms, a percutaneous biopsy result of the largest 
tumor showing that it is not poorly differentiated and, 
most significantly, no tumor size or number limitation. 
An important finding was that the 1-, 3- and 5-year 
actuarial survival rates in the group exceeding the Milan 
criteria vs. the group within them were 94%, 76% and 
69% vs. 95%, 82% and 78%, respectively (P=0,3). They 
also suggested that AFP > 500 ng/mL was associated 
with worse outcomes for both groups, and thus the AFP 
limitations should be included in the criteria for HCC 
patients meeting or exceeding the Milan criteria.
EMERGING CHALLENGES IN LIVER 
TRANSPLANTATION
The significant lack of grafts and the subsequent 
placement of future candidates in the waiting list 
for a donor organ may be a taxing process for the 
recipients and thus high “drop-out” rates (10-20%) 
have been reported48,49. As a result, the rationale of 
“bridging” therapy has been proposed, according 
to which another therapeutic method such as 
surgical resection, radiofrequency ablation (RFA), or 
transarterial chemoembolization (TACE), is utilized 
to act as a “bridge” for preventing tumor progression 
until a suitable graft becomes available. It is also 
generally accepted that the patient’s response to such 
treatments may be associated with the aggressiveness 
of the disease and thus could possibly be utilized as a 
surrogate marker for prognosis. Despite the fact that 
no firm conclusions can yet be made, data suggest 
that this process can increase patient survival and 
decrease tumor recurrence post-OLT50.
However, a fair percentage of HCC patients do not 
even get close to being placed in the waiting list due to 
their advanced stage disease. Therefore, downstaging 
of HCC by liver-directed therapies, such as RFA, TACE, 
transarterial radioembolization (TARE), stereotactic 
body radiation (SBRT) or a combination of them, to 
within the Milan criteria has been proposed as the 
process of expanding the criteria has not yet reached 
a definitive conclusion. A recent study compared 
the survival outcomes between patients presenting 
initially within the Milan criteria and patients receiving 
locoregional treatments in order to be downstaged to 
within the Milan criteria51. It was reported that survival 
rates were similar between the two study arms. 
Interestingly, a percentage of the patients beyond the 
Milan criteria after downstaging received resection 
after being downstaged, and were able to avoid OLT. 
On the other hand, a systematic review showed that 
almost half of the patients outside the Milan criteria 
can be successfully downstaged, but it seems that 
they exhibit higher recurrence rates, when compared 
to those meeting the Milan criteria52. Due to the vast 
heterogeneity of the studies, larger prospective ones 
with standardized reporting criteria need to be carried 
out in order to achieve robust and trustworthy results.
Also, living donor liver transplantation (LDLT) 
represents an alternative to the lengthy period on 
the waiting list for a donor organ and may pose 
acceptable threat to the donor’s health if performed 
in qualified and specialized centers. Specifically, donor 
mortality has been estimated around 0.1-0.3% for 
right lobe grafts53,54, while the reported risk of donor 
fatal complication is around 2-10%55–57.LDLT comprises 
the majority of liver transplantations performed in 
Asian countries in contrast to Western countries58. This 
however does not mean that we should take lightly 
this type of donation, as we are referring to donors 
who are healthy and enter a surgery where there will 
be no benefit to their health, a truly altruistic act. This 
type of OLT does not impose further on the lack of 
grafts, because it is personal issue between patients 
and their relatives or close contacts (according to the 
existing legal system in each country) and as such 
selection criteria should be set based on the tumor’s 
characteristics and each case should be managed 
uniquely. That is partly the reason why so many 
Asian centers proposed their own criteria for LDLT, 
as discussed above. A systematic review and meta-
analysis comparing LDLT vs. DDLT reported a hazard 
ratio (HR) of 0.97 for overall survival (95% CI 0.73-1.27, 
P=0.8) and a HR of 1.59 for disease-free survival (95% 
CI 1.02-2.49, P=0.041), indicating a possible superiority 
of DDLT over LDLT in terms of disease-free survival59.
The use of marginal or extended-criteria organs is 
another way to enlarge the liver donor pool (Table 2)60. 
These are organs with high risk of complications, for 
instance primary dysfunction, delayed graft function 
or biliary complications61. This category incorporates 
organs from split livers, non-heart beating donors, 
elderly donors and HCV-infected donors62–66.
In split liver transplantation (SLT) the liver from a 
deceased donor is divided: a) between a pediatric 
and an adult recipient or b) between a small adult 
or big child and a medium-sized adult. A fact that 
should be mentioned is that these grafts need to 
undergo a regeneration process, which may trigger 
the proliferation and growth of a tumor67. In spite of 

















the disbelief lurking behind the split livers, a recently 
published study indicates that when compared 
to whole-grafts, split livers demonstrated similar 
survival rates, as well as prevalence and severity 
of complications, as long as donors were carefully 
selected and matched to recipients and the surgical 
skills were of high expertise68.
The utilization of donor organs from non-heart beating 
donors (NHBD), or otherwise known as donation after 
circulatory death (DCD), currently corresponds to 
around 20% of the grafts used for transplantation in 
Europe69. One version of this is the controlled DCD, 
when the heart stops after removal of the life support70 
and another is the uncontrolled DCD, in which 
unexpected heart arrest occurs and organ recovery 
takes place after failure of resuscitation71. Regardless 
of the case, in contrast to the conventional DDLT 
after brain death, CDC is accompanied by ischemia 
reperfusion injury, which is thought of having pro-
oncogenic and tumor proliferation promoting effects, 
thus predisposing to poorer oncological outcomes72. 
Additionally, the incidence of biliary adverse events is 
thought to increase as well73.
HCV-infected donors could also be accepted for 
OLT under certain circumstances. Even though only 
5% of the donors seem to be HCV-positive, such a 
utilization can decrease mortality on the waiting 
list and limit organ shortage, while studies have 
shown similar graft and patient survival rates when 
compared to HCV-negative donors, except for 
HCV-HIV co infected recipients66. A new age of OLT 
is upon us with the introduction of direct-acting 
antivirals (DAA) either pre- or post-OLT, which have 
shown to be efficacious and safe and to decrease 
the number of HCV-infected donors with positive 
HCV-RNA, thus reducing transmission rates, as well 
as the number of HCV-related HCC patients on the 
waiting list66,74. Nevertheless, before proceeding 
with the acceptance of HCV-positive donors for OLT 
in HCC patients, issues regarding viral extirpation 
and HCC recurrence need to be resolved75.
The use of grafts from elderly donors or the use of 
steatotic organs is also an alternative way to increase 
the liver donor pool. Unfortunately, this method can 
result in a high risk of HCC recurrence, if by reducing 
the waiting time, the biological evolution of the 
tumor’s behavior is underestimated76,77. Also, criteria 
regarding this strategy have been evolving over time, 
with some organs being acceptable grafts in some 
geographical regions yet unacceptable in others, 
hence highlighting the steps needed to be made in this 
field of research. Currently, although age may affect 
certain parameters, there is no limitation in terms of 
age78, whereas steatosis up to a certain degree (usually 
macrosteatosis of 40%) is considered acceptable63.
TUMOR BIOLOGY: ANASPECT TO BE INCLUDED 
IN THE CRITERIA
The overreaching aim of OLT is to prevent HCC 
from recurring.  Consequently, what we should aim 
for is how to predict tumor biologic behavior and 
recurrence prior to transplantation, so that HCC 
patients with optimal characteristics can benefit 
the most and demonstrate increased survival rates. 
This has become widely acceptable, hence the latest 
tendency to include biological tumor markers in the 
different criteria suggested.
The histopathological examination of the explant 
reveals the biology of the tumor by assessing 
microvascular invasion and tumor grade. However, it 
would be preferable to evaluate these findings prior 
to transplantation, as they correlate with recurrent 
disease prognosis13. DuBay et al[46] included 
percutaneous biopsy in their criteria (Toronto), which 
did not impose any limitation to tumor number or 
size, in order to avoid OLT in patients with poorly 
differentiated HCC. Although, as previously discussed, 
these were further validated (extended Toronto 
criteria) by Sapisochin et al47, the vast heterogeneity 
of HCC, the low sensitivity of biopsy and the potential 
for bleeding or even needle track seeding, render 
routine biopsy not an easily recommended action79. 
Additionally, patients with decompensated cirrhosis 
may not be able to undergo biopsy owing to retention 
of ascites. As a result, noninvasive methods, such as 
markers and PET, should be preferred.
The utility of 18-FDG-PET in determining tumor 
biology has been shown by Kornberg et al80. They 
reported that pre-OLT factors with high predictive 
value for recurrence-free survival were: negative PET 
uptake, AFP < 400 IU/mL and total tumor diameter 
< 10 cm. Significantly, PET-positive findings were the 
only independent factor predictive of cancer-related 
patient drop-out from the waiting list. On this basis, 
Lee et al45 proposed the aforementioned NCCK criteria.
Regarding the remaining surrogate tumor markers, 
AFP and DCP are the most commonly implemented. 
AFP is included as a parameter of several criteria 
around the world, such as Hangzhou, TTV/AFP, TTD-
AFP and Warsaw as mentioned in Table 1. Besides, 
the international consensus highlighted that AFP 

















resembles a marker with high prognostic value79. In 
Japan, DCP predominates as a tumor marker. This has 
become apparent by its inclusion in several Japanese 
criteria, such as Kyoto and Kyushu (Table 1). It has been 
associated with histopathological findings, i.e. invasion 
of portal vein81,82 or high grade HCC differentiation83.
In addition, Fujiki et al84 showed that DCP levels are 
superior to pre-OLT tumor size or number regarding 
prognosis and recurrence, as well as that it correlates 
with histopathological characteristics and thus patient 
selection should depend on DCP levels. Besides, Todo 
et al85 used both AFP and DCP as serological markers 
and both correlated with the biological behavior of 
HCC, while patients with AFP ≤ 200 ng/mL and DCP ≤ 
100 mAU/mL exhibited better prognosis. Interestingly, 
a study published by Feng et al86 in March 2017, 
proposed a novel model for predicting early recurrence 
of HCC within the Milan criteria after OLT. This included 
the combination of AFP levels (cut-off value: 321 ng/
mL) and cytokeratin-19 (CK19)/glypican-3 (GPC3) sub-
typing within the Milan criteria. It could potentially be 
found to be helpful in patient selection based on pre-
OLT needle core biopsy.
Angiogenesis and tumor invasion are partially 
mediated by inflammation-induced upregulation 
of cytokines87. Angiogenesis plays an important 
role in HCC, thus inflammatory mediators could not 
be omitted from the search of surrogate markers. 
Specifically, pre-transplant NLR has been shown to 
correlate with HCC recurrence post-OLT88,89. An et 
al also reported that CRP levels equal to or above 1 
mg/dL were related to tumor recurrence90, while this 
could not be proven by others89.  Both NLR and CRP 
are included in the criteria proposed by Na et al41. 
However, their implementation is still controversial, as 
they reflect the tumor’s microenvironment, which may 
be altered by several irrelevant factors, i.e. infection, 
hence further research is needed on this field.
We previously mentioned that response to pre-OLT 
treatments, either in terms of bridging therapy or 
downstaging, may also serve as a surrogate marker 
for HCC recurrence. Response to such locoregional 
treatments, according to the EASL-EORTC guidelines, 
should be evaluated by modifications in serum AFP 
levels or radiological changes based on the modified 
Response Evaluation Criteria in Solid Tumors (mRECIST)9. 
Additionally, according to a European multicenter study 
assessing 306 HCC patients meeting the Milan criteria 
and 116 exceeding them after locoregional therapies (for 
bridging or downstaging purpose) and OLT, those two 
factors were indeed the most useful in the prognosis of 
HCC recurrence after OLT.
Tabla 2. Advantages and disadvantages of different liver donor sources for liver transplantation in HCC by Sapisochin et al60.
SOURCE ADVANTAGES DISADVANTAGES
Living donor liver 
transplantation
• Reduced drop-out rates (if donor graft 
available)
• Unlimited donor source
• Immunological benefits
• Reduced waiting time (if donor graft available)
• Donor’s health risk




• Reduced waiting time
• Elevated HCC recurrence risk owing to liver 
regeneration?
• Elevated risk of biliary adverse events
Non-heart beating 
donors
• Reduced waiting time
• Low MELD score patients may demonstrate 
fewer adverse events
• Elevated rates of adverse events
• Elevated risk of graft loss
• Biliary strictures





































CRITERIA YEAR COUNTRY DDLT LDLT OS RFS
Milan10 1996 Italy 48 0






UCSF15 2001 USA 70 0
one ≤ 6,5 cm or ≤ three with the largest one 
≤ 4,5 cm in diameter and an overall tumor 
diameter ≤ 8 cm
75,2% --
CUN19 2001 Spain 47 0 one ≤ 6 cm, or up to three ≤ 5 cm 79%
70%
(3-year)
Mount-Sinai20 2002 USA 43 0
any number of lesions, each 5-7 cm in 
diameter
-- 55%
Edmonton21 2004 Canada 40 0






Dallas22 2007 USA 1206 0
one ≤ 6 cm, or two to four each ≤ 5 cm in 
diameter
-- 63,9%-64,6%
Tokyo23 2007 Japan 0 78 ≤ five tumors not exceeding 5cm in diameter 75% 90%
Kyoto27 2007 Japan 0 125
≤ ten tumors all of which ≤ 5 cm in diameter 




2007 Japan 0 60





Hangzhou30 2008 China 195 0
a) ≤ 8 cm in diameter, or b) >8 cm in 
diameter, histopathologic grade I or II and 






≤ 5cm in diameter, ≤ six nodules and no 
gross vascular invasion
76,3% --
Valencia34 2008 Spain 257 0
≤ three lesions, each ≤ 5 cm in diameter, total 
diameter ≤ 10 cm
67% --
Shanghai35 2009 China 1074 4
one ≤ 9 cm in diameter, or no more than 
three nodules with the largest ≤ 5 cm in 
diameter, overall tumor diameter ≤ 9 cm 
without extrahepatic metastasis, lymph node 
or macrovascular invasion
78,1% 52,6%
Up-to-714 2009 Italy 1404 121
sum of tumor number and size of the 
largest nodule ≤ 7 cm in diameter, without 
microvascular invasion
71,2% --
TTV/AFP36 2009 Canada 6478 0
total tumor volume ≤ 115 cm3 and AFP ≤ 400 
ng/mL
-- --
AFP-TTD38 2012 Italy 158 0
total tumor diameter ≤ 8 cm and AFP ≤ 400 
ng/mL
-- 74,4%
Warsaw39 2014 Poland 121 0
beyond Milan, but within UCSF or up-to-7 










negative PET/CT findings and total tumor 




2016 Canada 210 0
no size-number limitation, no vascular 
invasion nor extrahepatic disease, no cancer-
related symptoms, biopsy of the largest 






Tabla 1. Liver transplantation selection criteria for patients with hepatocellular carcinoma  in different centers.

















Abbreviations: DDLT: deceased donor liver 
transplantation; LDLT: living donor liver 
transplantation; OS: overall survival; RFS: recurrence-
free survival; UCSF: University of California, San 
Francisco; CUN: University Clinic of Navarra; DCP: des-
Gamma-carboxy prothrombin; AFP: a-fetoprotein; 
TTV: total tumor volume; TTD: total tumor diameter; 
NLR: neutrophil-lymphocyte ratio; CRP: C-reactive 
protein; PET/CT: positron emission tomography/
computed tomography.
Abbreviations: MELD: model for end-stage liver disease
CONCLUSIÓN
Liver transplantation has witnessed great progress 
over the past few decades. The Milan criteria, although 
proposed more than 20 years ago, still remain the 
gold-standard for patient selection. Nevertheless, 
many HCC patients that could possibly benefit from 
OLT with acceptable survival rates do not have access 
to the waiting list due to the restrictive character of 
those criteria. Scientists, researchers and surgeons 
from all over the world attempted to expand them 
with acceptable oncologic and survival outcomes, but 
it soon became apparent that the effort of expanding 
the OLT criteria further and further resembles the price 
of a metro ticket. Just as the longer distance you travel, 
the more you must pay for the ticket, similarly the 
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higher the acceptable tumor diameter, the higher the 
recurrence rates. On the other hand, expanding the 
donor liver pool has been tried out by implementing 
grafts from living, non-heart beating, steatotic, elderly, 
HCV-infected donors or even split livers, but more 
research is needed so as to achieve optimal outcomes, 
as with the conventional brain dead donors. As in 
many aspects of medicine, the future of OLT relies 
on molecular markers, which could be utilized in an 
effort to effectively predict HCC recurrence after liver 
transplantation.
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